<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37051964</PMID><DateCompleted><Year>2023</Year><Month>04</Month><Day>14</Day></DateCompleted><DateRevised><Year>2023</Year><Month>06</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2050-0521</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>4</Issue><PubDate><Year>2022</Year><Month>Oct</Month><Day>01</Day></PubDate></JournalIssue><Title>Sexual medicine reviews</Title><ISOAbbreviation>Sex Med Rev</ISOAbbreviation></Journal><ArticleTitle>Treatment of Sexual Dysfunction in Women with Systemic Autoimmune Rheumatic Disorders: A Systematic Review.</ArticleTitle><Pagination><StartPage>520</StartPage><EndPage>528</EndPage><MedlinePgn>520-528</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.sxmr.2022.08.002</ELocationID><Abstract><AbstractText Label="INTRODUCTION">Female sexual dysfunction (SD) is an under-recognized and undertreated problem in patients with systemic autoimmune rheumatic disorders (SARDs).</AbstractText><AbstractText Label="OBJECTIVES">To summarize and evaluate the existing treatment modalities for SD in females with SARDs.</AbstractText><AbstractText Label="METHODS">A systematic review was conducted following the PRISMA guidelines. Electronic databases were searched up to April 2022 for studies that assessed the use of pharmacological and non-pharmacological treatment modalities for the management of SD in females with SARDs. Randomized and observational studies were included. (PROSPERO: CRD42022296381).</AbstractText><AbstractText Label="RESULTS">Seven studies with 426 females with SD were included. Seven different treatment modalities belonging to 5 different classes (androgen therapy, phosphodiesterase-5 inhibitors, exercise, education and local creams) were evaluated in patients with systemic lupus erythematosus, rheumatoid arthritis and systemic sclerosis. The majority of the studies were of low methodological quality. Standardized patient education and 8-week aerobic walking programs were successful in improving female SD. Local creams improved dyspareunia in females with systemic sclerosis. Testosterone did not significantly improve SD in patients with systemic lupus erythematosus. Accordingly, tadalafil did not result in a significant improvement of SD in females with systemic sclerosis, based on the Female Sexual Function Index.</AbstractText><AbstractText Label="CONCLUSION">There is a lack of sufficient evidence to recommend a certain management strategy for SD in females with SARDs. Nonpharmacological therapy and lubricant creams may be beneficial in females with SARDs. No benefit was demonstrated after androgen therapy or tadalafil. Still, no definite conclusions can be drawn due to the important limitations of the available literature. Overall, our results may be considered preliminary and further research in the field is mandatory.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022, International Society for Sexual Medicine. Published by Elsevier.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Baniotopoulos</LastName><ForeName>Pantelis</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>GKT School of Medical Education King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pyrgidis</LastName><ForeName>Nikolaos</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Urology 'Martha-Maria' Hospital Nuremberg, Nuremberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Minopoulou</LastName><ForeName>Ioanna</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Fourth Department of Internal Medicine Medical School Hippokration General Hospital Aristotle University of Thessaloniki, Thessalon&#xed;ki, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tishukov</LastName><ForeName>Maksim</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Medical School Aristotle University of Thessaloniki, Thessaloniki, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sokolakis</LastName><ForeName>Ioannis</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Urology 'Martha-Maria' Hospital Nuremberg, Nuremberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hatzichristodoulou</LastName><ForeName>Georgios</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Urology 'Martha-Maria' Hospital Nuremberg, Nuremberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dimitroulas</LastName><ForeName>Theodoros</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Fourth Department of Internal Medicine Medical School Hippokration General Hospital Aristotle University of Thessaloniki, Thessalon&#xed;ki, Greece.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Sex Med Rev</MedlineTA><NlmUniqueID>101614773</NlmUniqueID><ISSNLinking>2050-0521</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>742SXX0ICT</RegistryNumber><NameOfSubstance UI="D000068581">Tadalafil</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000728">Androgens</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000068581" MajorTopicYN="N">Tadalafil</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000728" MajorTopicYN="N">Androgens</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012595" MajorTopicYN="Y">Scleroderma, Systemic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012735" MajorTopicYN="Y">Sexual Dysfunction, Physiological</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Female Sexual Dysfunction</Keyword><Keyword MajorTopicYN="N">Rheumatic Diseases</Keyword><Keyword MajorTopicYN="N">Systematic Review</Keyword><Keyword MajorTopicYN="N">Systemic Autoimmune Rheumatic Disorders</Keyword></KeywordList><CoiStatement>Conflicts of interest: The authors report no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>5</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>8</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>4</Month><Day>14</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>13</Day><Hour>5</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37051964</ArticleId><ArticleId IdType="doi">10.1016/j.sxmr.2022.08.002</ArticleId><ArticleId IdType="pii">7016901</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>